iSpecimen Inc. (ISPC): Cost of Revenue
$1.90M
Year ended 2025-12-31
$971.1K
Trailing 12 months to 2026-06-30
-26.3%
3-year compound annual growth
-11.9%
5-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.90M | -64.1% | 2026-04-01, From 2025-01-01 |
| 2024-12-31 | $5.30M | +10.0% | 2026-04-01, From 2024-01-01 |
| 2023-12-31 | $4.82M | +1.3% | 2025-04-14, From 2023-01-01 |
| 2022-12-31 | $4.76M | -9.4% | 2024-03-13, From 2022-01-01 |
| 2021-12-31 | $5.25M | +46.4% | 2023-03-30, From 2021-01-01 |
| 2020-12-31 | $3.59M | n/a | 2022-03-22, From 2020-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| iSpecimen Inc. (ISPC) | 2025-12-31 | $1.90M | -64.1% |
| OneMedNet Corp (ONMD) | 2025-12-31 | $1.86M | +101.5% |
| Cannabis Bioscience International Holdings, Inc. (CBIH) | 2025-05-31 | $40.1K | -12.0% |
| MaxCyte, Inc. (MXCT) | 2025-12-31 | $6.22M | -12.4% |
| Incyte Corp (INCY) | 2025-12-31 | $372.13M | +19.2% |
| Icon PLC (ICLR) | 2024-12-31 | $5.85B | +2.2% |
| Weed, Inc. (BUDZ) | 2025-12-31 | $0 | n/a |
| Vitaspring Biomedical Co. Ltd. (VSBC) | 2026-01-31 | $0 | n/a |
Compare ISPC, ONMD, CBIH, MXCT side by side · Screen every company in Services-Commercial Physical & Biological Research ↗